Beijing, China – April 16, 2026 – The global healthcare industry is undergoing a profound transformation in 2026, fueled by supportive policies, cutting-edge technological breakthroughs and rising demand for high-quality medical services, according to the latest industry reports from Global Market Intelligence Inc. and medical industry associations. From AI-aided diagnosis integrated into medical insurance to the clinical landing of brain-computer interfaces, the industry is stepping into a new era of inclusive and intelligent development.
A landmark policy advancement emerged in early April 2026, when China’s National Healthcare Security Administration officially included AI-aided diagnosis services into the national medical insurance Category B catalog, becoming the world’s first policy to achieve full medical insurance coverage for AI diagnosis. This move marks the transition of AI medical technology from pilot exploration to large-scale popularization, covering 12 high-frequency clinical scenarios including lung nodule CT screening, diabetic retinopathy identification and automatic electrocardiogram analysis.
Clinical data shows that AI systems can complete a full lung scan and mark suspicious lesions within 40 seconds, improving reading efficiency by more than 60% compared with traditional manual reading and reducing the misdiagnosis rate of early cancer by 18%. The policy sets phased promotion goals, aiming to achieve full coverage of AI-aided diagnosis in tertiary hospitals by the end of 2026, extend to secondary hospitals and county-level medical consortia in 2027, and reach primary medical institutions by 2030, effectively addressing the shortage of medical talents at the grassroots level.
Technological breakthroughs have become a core driving force for industry growth, with brain-computer interface (BCI) technology leading the way. In March 2026, an implantable BCI hand movement function compensation system developed by a domestic enterprise obtained the world’s first Class III medical device registration certificate for invasive BCI, and was quickly included in the medical insurance reimbursement scope, gradually being promoted in Shanghai, Hubei and other regions. The system adopts epidural minimally invasive implantation technology, requiring no craniotomy, and only a coin-sized electrode device is implanted, with the operation time about 1 hour and the infection risk reduced by 90%.
Clinically, 68.75% of patients recovered manual grasping ability six months after surgery, with a 100% improvement rate, effectively helping patients with spinal cord injury and quadriplegia achieve self-care. With more than 3.7 million spinal cord injury patients in China and about 90,000 new cases each year, the landing of BCI technology not only meets the core rehabilitation needs of this group, but also provides a new path for the treatment of neurological diseases such as Parkinson’s disease and Alzheimer’s disease.
In the field of innovative drugs, the industry has ushered in a "golden period of high returns from innovation" driven by policy loosening. On April 14, 2026, the General Office of the State Council issued a document allowing high-value innovative drugs to set high prices in the early stage of listing, encouraging original innovation by allowing pharmaceutical companies to independently price and adjust prices dynamically. In the first quarter of 2026, 14 Class I innovative drugs were approved, an increase of 25% year-on-year, including the world’s first DLL3/CD3 bispecific antibody for small cell lung cancer and China’s first fully independent Class I radioactive innovative drug.
The global medical device market is also showing steady growth momentum. Data shows that the global medical device market size reached 648 billion US dollars in 2023, and is expected to exceed 765 billion US dollars by 2026, with a compound annual growth rate (CAGR) of 5.8%. Cardiovascular devices, orthopedic implants and in vitro diagnostics (IVD) remain the top three segments, accounting for more than 45% of the total market share. Meanwhile, surgical robots are accelerating their popularization, and the global market size is expected to reach 14 billion US dollars in 2026.
Smart hospitals are also reshaping the medical service model. The world’s first super AI hospital landed in Boao Lecheng, Hainan, realizing full-process intelligent diagnosis and treatment through an "online AI platform + offline medical consortium + full-cycle management" model. Patients can enjoy AI cloud accompaniment, time-sharing appointments and one-click settlement, reducing waiting time by 80%, while doctors benefit from clinical decision support systems that improve document efficiency by 50% and reduce medical errors.
Industry experts predict that the global healthcare industry will maintain strong growth momentum in the second half of 2026. The deep integration of AI technology with medical services, the continuous expansion of innovative drug R&D and the improvement of medical insurance systems will further promote industry upgrading. For enterprises, focusing on technological innovation and clinical demand will be the key to seizing market opportunities in the new round of development.